Information Provided By: 
Fly News Breaks for October 31, 2019
TFX
Oct 31, 2019 | 18:47 EDT
Piper Jaffray analyst Matt O'Brien kept his Overweight rating and $400 price target on Teleflex after its Q3 earnings beat and a narrowed higher guidance for FY19. The analyst notes that Urolift drove much of the beat and management reflected positively on expectations for 2020 with several new products contributing, including Urolift 2 and Manta. O'Brien adds that Teleflex remains "among the cleanest large cap growth stories" in his coverage universe.
News For TFX From the Last 2 Days
There are no results for your query TFX
